Hosted on MSN
With a New Take on an Old Schizophrenia Drug, LB Pharma Prepares IPO to Fund Phase 3 Test
Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...
As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines ...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities ...
Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva ...
Hello everybody, and welcome to the Q2 2026 Teva Pharmaceutical Industries Earnings Conference Call. My name is Elliot. I'll be coordinating your call today. [Operator Instructions] I would now like ...
Tirzepatide works the same way. It is the active ingredient in both Mounjaro and Zepbound, both made by Eli Lilly. Mounjaro ...
Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for ...
The FDA issued a nationwide Class II recall of levothyroxine, a common thyroid medication, due to concerns over potency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results